Drug Discovery Companies

Recursion Pharmaceuticals

Salt Lake City, United States

Recursion Pharmaceuticals leverages extensive biological and chemical datasets – exceeding 65 petabytes encompassing phenomics, transcriptomics, and patient data – to power its Recursion OS drug discovery platform. This platform utilizes computer vision, machine learning, and a proprietary supercomputer, BioHive-2, to analyze cellular images and predict drug efficacy, significantly accelerating hit identification and IND-enabling studies. Currently, Recursion is advancing a pipeline of potential therapies, including REC-3565 for B-cell lymphomas which is in Phase 1 clinical trials, and has established strategic partnerships with pharmaceutical and technology leaders to expand its AI-driven drug discovery capabilities.

Tempus AI

Chicago, United States

Tempus provides a platform combining comprehensive clinical and molecular data with artificial intelligence, primarily serving the oncology space. Their core offering is an operating system built upon the world’s largest library of such data, enhanced by recent advancements in generative AI like their clinical co-pilot, David, and digital pathology capabilities acquired through Paige. Tempus targets physicians, pharmaceutical companies, and patients seeking data-driven insights to improve cancer treatment decisions and accelerate drug development.

Xaira Therapeutics

San Francisco, United States

Xaira Therapeutics is building a generative AI platform focused on de novo protein design and drug candidate creation, leveraging advancements from the technology behind AlphaFold. The company’s core innovation lies in applying AI to not just predict protein structures, but to generate novel protein therapeutics with optimized properties for a range of diseases. Backed by a $1 billion Series A funding round, Xaira Therapeutics aims to accelerate drug discovery beyond traditional methods and is initially focusing on developing therapeutics for currently undruggable targets.

Insitro

South San Francisco, United States

Insitro leverages high-throughput phenotypic screening and machine learning to build predictive models of human biology, focusing initially on diseases like NASH and heart failure. Their platform combines large-scale experimental data – including cellular assays and human genetic data – with proprietary machine learning algorithms to identify and validate drug targets and predict clinical trial success. Notably, Insitro has established collaborations with pharmaceutical companies like Bristol Myers Squibb and Roche to apply their technology to specific disease areas and advance novel therapeutics.

Insilico Medicine

Hong Kong, Hong Kong

Insilico Medicine is a Hong Kong-based biotechnology company applying generative AI to accelerate the discovery and development of novel therapeutics. Their core technology is Pharma.AI, an end-to-end platform utilizing deep learning for target identification, molecule generation, and clinical trial prediction. Insilico Medicine focuses on discovering drugs for age-related diseases and extending healthy longevity, aiming to reduce the time and cost associated with traditional pharmaceutical R&D.

Valo Health

Boston, United States

Valo Health is a U.S.-based company applying artificial intelligence to accelerate pharmaceutical drug discovery and development. Their core product is the Opal Computational Platform™, which integrates machine learning with extensive human tissue and patient data to identify and advance potential drug candidates. Valo targets the pharmaceutical industry by offering a technology platform designed to reduce the time and cost associated with bringing novel therapies to market.

Lila Sciences

San Francisco, United States

Lila Sciences builds AI Science Factories - automated laboratories guided by AI for continual scientific discovery. Raised $350M Series A.

Owkin

Paris, France

Owkin is a French AI company focused on accelerating drug discovery and precision medicine through advanced analysis of complex biological data. Their core product, the K PRO platform, utilizes agentic AI – a system of autonomous AI agents – to uncover causal relationships within multimodal patient data sourced from leading research institutions. Owkin serves pharmaceutical companies and academic researchers seeking to improve R&D efficiency and identify novel therapeutic targets by leveraging AI-driven insights beyond traditional analytical methods.

Terray Therapeutics

Pasadena, United States

Terray Therapeutics combines high-throughput chemistry with AI for small molecule drug discovery at unprecedented scale.

BPGbio

Framingham, United States

BPGbio uses AI and causal machine learning for drug discovery and development. Named 2024 BioTech AI Company of the Year.

BioAge Labs

Richmond, United States

BioAge Labs is a US-based biotechnology company focused on developing therapeutics for cardiometabolic diseases by targeting the biological processes of aging. Their core technology is a human-first discovery platform that leverages decades of proprietary multi-omics data to identify and validate novel aging-related drug targets. Currently, BioAge is advancing BGE-102, a program targeting chronic inflammation, and a preclinical apelin receptor agonist with potential for significant weight loss, both aimed at addressing age-related metabolic dysfunction.

Atomwise

San Francisco, United States

Atomwise develops a deep learning platform, leveraging convolutional neural networks to predict the binding affinity of small molecules to proteins – accelerating the identification of potential drug candidates. Their AI superplatform virtually screens trillions of compounds, identifying novel molecules with potential in areas like immune and inflammatory diseases, and has resulted in multiple programs advancing towards clinical development. Notably, Atomwise has partnered with organizations like the National Institutes of Health and has demonstrated success in repurposing existing drugs for new applications, including identifying potential treatments for Ebola and COVID-19.

Verge Genomics

San Francisco, United States

Verge Genomics has developed CONVERGE®, an AI-powered drug discovery platform utilizing a large, proprietary human multi-omics database to identify and validate drug candidates for neurodegenerative diseases. Their platform leverages machine learning to analyze human tissue data, enabling the rapid identification of novel targets and accelerating drug development – most notably, their lead compound VRG50635, a PIKfyve inhibitor for ALS, entered clinical trials just four years after initial research. Currently focused on ALS, Parkinson’s Disease, and Frontotemporal Dementia, Verge aims to deliver breakthrough treatments for diseases with limited or no effective therapies.

EvolutionaryScale

New York, United States

EvolutionaryScale develops generative AI models for de novo protein design and understanding, most notably the ESM-3 family of protein language models. Their core innovation lies in leveraging large-scale protein sequence data to enable the creation of novel proteins with desired functions – demonstrated by the successful in silico design and synthesis of esmGFP, a fluorescent protein evolved beyond natural limitations. Targeting pharmaceutical companies, biotechnology firms, and academic research labs, EvolutionaryScale provides access to ESM-3 via API and open-source models (ESM-3-open) to accelerate drug discovery and protein engineering efforts, backed by $142M in seed funding.

Healx

Cambridge, United Kingdom

Healx is a UK-based company applying artificial intelligence to accelerate drug discovery for rare diseases. Their core technology utilizes AI-driven drug repurposing – identifying and developing existing compounds for new applications – to build a pipeline of potential therapies. Healx focuses on addressing the 90% of rare diseases lacking treatment by de-risking the drug development process and efficiently scaling programs for conditions with limited patient populations.

Cradle

Amsterdam, Netherlands

Cradle develops a generative AI platform for de novo protein design, enabling researchers to create and optimize proteins with desired properties. Their technology utilizes machine learning models trained on proprietary and user-supplied experimental data to generate novel protein sequences and predict their characteristics, accelerating the drug discovery and protein engineering processes. Cradle targets biotechnology and pharmaceutical companies, and their platform aims to reduce the time and cost associated with traditional protein development pipelines by minimizing the need for iterative lab experiments.

Genesis Therapeutics

Burlingame, United States

Genesis Therapeutics is a U.S.-based biotech company focused on de novo drug design for previously intractable protein targets. Their core technology is GEMS, a proprietary molecular AI platform integrating AI and physics-based modeling to generate highly potent and selective drug candidates. Genesis Therapeutics targets pharmaceutical companies and research institutions seeking to accelerate discovery for complex targets that have historically proven difficult to address with traditional methods.

54gene

Lagos, Nigeria

54gene builds a pan-African genomic database to improve drug discovery and development for diseases disproportionately impacting African populations. Utilizing AI-powered analysis of this data, they identify genetic factors relevant to disease and accelerate the creation of targeted therapeutics. Their unique value proposition lies in addressing the significant underrepresentation of African genomes in existing biomedical research, enabling more effective and equitable healthcare solutions.

Atomic AI

San Francisco, United States

Atomic AI is a U.S.-based biotechnology company focused on discovering novel RNA-targeted therapeutics. Their core technology is a deep learning platform that integrates computational modeling with proprietary wet-lab assays to identify and develop small molecule drugs and RNA-based medicines. Atomic AI targets pharmaceutical companies and research institutions seeking to expand their pipelines with innovative RNA-focused therapies.

Bioptimus

Paris, France

Bioptimus is building universal AI foundation models for biology. Their models understand biological systems to accelerate drug discovery and healthcare innovation.

Profluent

Berkeley, United States

Profluent uses large language models to design novel proteins for therapeutic applications. Developed OpenCRISPR, the first AI-designed gene editor used to edit human genomes.

Intelligencia AI

Athens, Greece

Intelligencia uses AI to predict clinical trial outcomes and optimize drug development strategies for pharmaceutical companies.

BenevolentAI

London, United Kingdom

BenevolentAI is a UK-based company that leverages a proprietary knowledge graph and machine learning to accelerate drug discovery and development. Their platform analyzes complex biomedical data and scientific literature to identify promising drug candidates and targets, supporting R&D decisions for pharmaceutical and biotechnology companies. BenevolentAI differentiates itself through a decade of investment in building a uniquely comprehensive and interconnected life science intelligence system.

Exscientia

Oxford, United Kingdom

Recursion is a clinical-stage technology company applying artificial intelligence to drug discovery and development. Their Recursion OS platform integrates extensive biological and chemical datasets – exceeding 65 petabytes – with automated experimentation and machine learning to rapidly identify drug candidates and optimize molecule design. Targeting conditions with high unmet need like cancer and rare diseases, Recursion aims to significantly improve the efficiency and reduce the failure rate traditionally associated with pharmaceutical research.

Isomorphic Labs

London, United Kingdom

Isomorphic Labs is a UK-based AI company applying advanced machine learning to accelerate drug discovery and molecular design. Building upon the AlphaFold protein structure prediction technology, they develop predictive and generative AI models to design novel molecules and anticipate drug performance. Their focus is on leveraging AI to address complex diseases and fundamentally transform the pharmaceutical research process for potential breakthroughs in medicine.

InstaDeep

Tunis, Tunisia

InstaDeep develops AI-powered decision-making systems, specializing in deep reinforcement learning and combinatorial optimization algorithms like those used in their DeepMind-collaborated protein folding work with AlphaFold. Their technology is applied to complex challenges in life sciences – notably demonstrated by their collaboration with BioNTech to accelerate drug discovery and vaccine development – and industrial applications like logistics and supply chain optimization. Acquired by BioNTech in 2023, InstaDeep leverages GPU-accelerated computing and has achieved research breakthroughs presented at leading AI conferences like NeurIPS, solidifying their position as a leader in applied AI research.

Anivance AI integrates miniaturized human organ systems on chips with Multi-Agent AI to accelerate drug discovery, backed by 35 patents.

Veeva Systems

Pleasanton, United States

Veeva Systems provides cloud-based software solutions specifically for the life sciences industry, encompassing research & development, quality management, and commercial operations. Their core offering is a unified clinical platform leveraging AI and data analytics to accelerate study timelines, streamline regulatory compliance, and improve data quality. Veeva targets pharmaceutical and biotechnology companies of all sizes, offering a consolidated system to manage critical processes from drug development through commercialization.